EGFR autophosphorylation but not protein score correlates with histologic and molecular subtypes in lung adenocarcinoma

Judit Moldvay, Tamás Barbai, Krisztina Bogos, Violetta Piurko, János Fillinger, Helmut H. Popper, J. Tímár

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Established clinicopathologic characteristics of non- small cell lung cancer patients define a subgroup responding better to EGFR-TK inhibitors: adenocarcinoma histology, ethnicity, sex, smoking status, presence of activating EGFR mutation, and/or K-RAS wild type. However, EGFR mutation does not automatically lead to increased activity of the protein influenced by several factors. As adenocarcinoma can be further divided into histologic subclasses, we compared adenocarcinomas without lepidic growth pattern (NLAC) to those characterized by pure or predominant lepidic growth (LAC) for EGFR protein expression and autophosphorylation activity (Y1173), as determined by immunohistochemistry. This pretarget therapy cohort comprised a total of 110 surgically operated patients of stage I non-small cell lung cancer: 49 NLAC and 61 LAC variants. The LAC group had a significantly better prognosis and the incidence of phospho-EGFR-positive tumors was significantly higher compared with NLAC. Patient sex did not influence EGFR activity, but the incidence of pEGFRpositive tumors was significantly lower among smoker patients. There was no statistically significant difference in EGFR or KRAS mutation frequencies between the 2 groups. In NLAC, pEGFR-positive tumors occurred exclusively among EGFRmutant/ K-RAS wild-type tumors. On the contrary, in LAC tumors, pEGFR-positive tumors were similarly frequent in the EGFR or K-RAS mutant groups indicating an interesting feedback activation of EGFR signaling in K-RAS mutant tumors. Our data also indicate that EGFR mutation leads to EGFR autophosphorylation only in a small fraction of adenocarcinoma patients, which might have clinical significance.

Original languageEnglish
Pages (from-to)204-209
Number of pages6
JournalDiagnostic Molecular Pathology
Volume22
Issue number4
DOIs
Publication statusPublished - 2013

Fingerprint

Adenocarcinoma
Neoplasms
Proteins
Non-Small Cell Lung Carcinoma
Mutation
Incidence
Mutation Rate
Growth
Adenocarcinoma of lung
Histology
Smoking
Immunohistochemistry
Therapeutics

Keywords

  • Autophosphorylation
  • EGFR
  • Immunohistochemistry
  • K-RAS
  • Lung adenocarcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology
  • Molecular Biology

Cite this

EGFR autophosphorylation but not protein score correlates with histologic and molecular subtypes in lung adenocarcinoma. / Moldvay, Judit; Barbai, Tamás; Bogos, Krisztina; Piurko, Violetta; Fillinger, János; Popper, Helmut H.; Tímár, J.

In: Diagnostic Molecular Pathology, Vol. 22, No. 4, 2013, p. 204-209.

Research output: Contribution to journalArticle

Moldvay, Judit ; Barbai, Tamás ; Bogos, Krisztina ; Piurko, Violetta ; Fillinger, János ; Popper, Helmut H. ; Tímár, J. / EGFR autophosphorylation but not protein score correlates with histologic and molecular subtypes in lung adenocarcinoma. In: Diagnostic Molecular Pathology. 2013 ; Vol. 22, No. 4. pp. 204-209.
@article{dd62d913450a43c0bddbeea7e527a49d,
title = "EGFR autophosphorylation but not protein score correlates with histologic and molecular subtypes in lung adenocarcinoma",
abstract = "Established clinicopathologic characteristics of non- small cell lung cancer patients define a subgroup responding better to EGFR-TK inhibitors: adenocarcinoma histology, ethnicity, sex, smoking status, presence of activating EGFR mutation, and/or K-RAS wild type. However, EGFR mutation does not automatically lead to increased activity of the protein influenced by several factors. As adenocarcinoma can be further divided into histologic subclasses, we compared adenocarcinomas without lepidic growth pattern (NLAC) to those characterized by pure or predominant lepidic growth (LAC) for EGFR protein expression and autophosphorylation activity (Y1173), as determined by immunohistochemistry. This pretarget therapy cohort comprised a total of 110 surgically operated patients of stage I non-small cell lung cancer: 49 NLAC and 61 LAC variants. The LAC group had a significantly better prognosis and the incidence of phospho-EGFR-positive tumors was significantly higher compared with NLAC. Patient sex did not influence EGFR activity, but the incidence of pEGFRpositive tumors was significantly lower among smoker patients. There was no statistically significant difference in EGFR or KRAS mutation frequencies between the 2 groups. In NLAC, pEGFR-positive tumors occurred exclusively among EGFRmutant/ K-RAS wild-type tumors. On the contrary, in LAC tumors, pEGFR-positive tumors were similarly frequent in the EGFR or K-RAS mutant groups indicating an interesting feedback activation of EGFR signaling in K-RAS mutant tumors. Our data also indicate that EGFR mutation leads to EGFR autophosphorylation only in a small fraction of adenocarcinoma patients, which might have clinical significance.",
keywords = "Autophosphorylation, EGFR, Immunohistochemistry, K-RAS, Lung adenocarcinoma",
author = "Judit Moldvay and Tam{\'a}s Barbai and Krisztina Bogos and Violetta Piurko and J{\'a}nos Fillinger and Popper, {Helmut H.} and J. T{\'i}m{\'a}r",
year = "2013",
doi = "10.1097/PDM.0b013e3182936957",
language = "English",
volume = "22",
pages = "204--209",
journal = "Diagnostic Molecular Pathology",
issn = "1052-9551",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - EGFR autophosphorylation but not protein score correlates with histologic and molecular subtypes in lung adenocarcinoma

AU - Moldvay, Judit

AU - Barbai, Tamás

AU - Bogos, Krisztina

AU - Piurko, Violetta

AU - Fillinger, János

AU - Popper, Helmut H.

AU - Tímár, J.

PY - 2013

Y1 - 2013

N2 - Established clinicopathologic characteristics of non- small cell lung cancer patients define a subgroup responding better to EGFR-TK inhibitors: adenocarcinoma histology, ethnicity, sex, smoking status, presence of activating EGFR mutation, and/or K-RAS wild type. However, EGFR mutation does not automatically lead to increased activity of the protein influenced by several factors. As adenocarcinoma can be further divided into histologic subclasses, we compared adenocarcinomas without lepidic growth pattern (NLAC) to those characterized by pure or predominant lepidic growth (LAC) for EGFR protein expression and autophosphorylation activity (Y1173), as determined by immunohistochemistry. This pretarget therapy cohort comprised a total of 110 surgically operated patients of stage I non-small cell lung cancer: 49 NLAC and 61 LAC variants. The LAC group had a significantly better prognosis and the incidence of phospho-EGFR-positive tumors was significantly higher compared with NLAC. Patient sex did not influence EGFR activity, but the incidence of pEGFRpositive tumors was significantly lower among smoker patients. There was no statistically significant difference in EGFR or KRAS mutation frequencies between the 2 groups. In NLAC, pEGFR-positive tumors occurred exclusively among EGFRmutant/ K-RAS wild-type tumors. On the contrary, in LAC tumors, pEGFR-positive tumors were similarly frequent in the EGFR or K-RAS mutant groups indicating an interesting feedback activation of EGFR signaling in K-RAS mutant tumors. Our data also indicate that EGFR mutation leads to EGFR autophosphorylation only in a small fraction of adenocarcinoma patients, which might have clinical significance.

AB - Established clinicopathologic characteristics of non- small cell lung cancer patients define a subgroup responding better to EGFR-TK inhibitors: adenocarcinoma histology, ethnicity, sex, smoking status, presence of activating EGFR mutation, and/or K-RAS wild type. However, EGFR mutation does not automatically lead to increased activity of the protein influenced by several factors. As adenocarcinoma can be further divided into histologic subclasses, we compared adenocarcinomas without lepidic growth pattern (NLAC) to those characterized by pure or predominant lepidic growth (LAC) for EGFR protein expression and autophosphorylation activity (Y1173), as determined by immunohistochemistry. This pretarget therapy cohort comprised a total of 110 surgically operated patients of stage I non-small cell lung cancer: 49 NLAC and 61 LAC variants. The LAC group had a significantly better prognosis and the incidence of phospho-EGFR-positive tumors was significantly higher compared with NLAC. Patient sex did not influence EGFR activity, but the incidence of pEGFRpositive tumors was significantly lower among smoker patients. There was no statistically significant difference in EGFR or KRAS mutation frequencies between the 2 groups. In NLAC, pEGFR-positive tumors occurred exclusively among EGFRmutant/ K-RAS wild-type tumors. On the contrary, in LAC tumors, pEGFR-positive tumors were similarly frequent in the EGFR or K-RAS mutant groups indicating an interesting feedback activation of EGFR signaling in K-RAS mutant tumors. Our data also indicate that EGFR mutation leads to EGFR autophosphorylation only in a small fraction of adenocarcinoma patients, which might have clinical significance.

KW - Autophosphorylation

KW - EGFR

KW - Immunohistochemistry

KW - K-RAS

KW - Lung adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=84892726596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892726596&partnerID=8YFLogxK

U2 - 10.1097/PDM.0b013e3182936957

DO - 10.1097/PDM.0b013e3182936957

M3 - Article

C2 - 24193009

AN - SCOPUS:84892726596

VL - 22

SP - 204

EP - 209

JO - Diagnostic Molecular Pathology

JF - Diagnostic Molecular Pathology

SN - 1052-9551

IS - 4

ER -